ZT: Why Shares of Cassava Sciences Rose 15% Today？

Why Shares of Cassava Sciences Rose 15% Today?
09/23/2021

"...

So what?

In its press release yesterday, Cassava noted that to "emphasize impartiality, changes in ADAS-Cog scores baseline to month 12 were independently analyzed by two consulting biostatisticians." That language might not be enough to assuage doubters.

在昨天的新闻稿中，Cassava 指出，为了“强调公正性，两位咨询生物统计学家独立分析了 ADAS-Cog 分数基线到第 12 个月的变化。”这种语言可能不足以安抚怀疑者。

It's an open-label study. That means both the volunteer and the researcher know that the patient is receiving the treatment. It's the opposite of the gold-standard double-blind study the FDA usually requires for approval, where no one knows who is getting a placebo. Cassava is comparing results to a 2010 study of Alzheimer's patients that did include a placebo cohort. The company noted that "we look forward to the initiation of a randomized, double-blind, placebo-controlled pivotal Phase 3 clinical program with simufilam in people with Alzheimer’s disease.”

这是一项开放标签研究。这意味着志愿者和研究人员都知道患者正在接受治疗。这与 FDA 通常要求批准的金标准双盲研究相反，在这种研究中，没有人知道谁在服用安慰剂。木薯正在将结果与 2010 年对阿尔茨海默病患者的研究进行比较，该研究确实包括安慰剂队列。该公司指出，“我们期待在阿尔茨海默病患者中启动一项随机、双盲、安慰剂对照的关键性 3 期临床项目，使用 simufilam。”

One bright spot is that the data continues to prove there are no safety concerns with patients receiving simufilam. Management says it's on track to begin a more robust phase 3 trial sometime in the final quarter of this year.

一个亮点是数据继续证明接受 simufilam 的患者没有安全问题。管理层表示，它有望在今年最后一个季度的某个时候开始更强大的第 3 阶段试验。

Web reference: https://www.fool.com/investing/2021/09/23/why-shares-of-cassava-sciences-rose-15-today/

信息分享，并非投资指南！